Product Information
LANSOPRAZOL-AMOXICIL-CLARITHRO is a generic product labeled by Rising Pharma Holdings Inc., priced at $6.0422 per EA under NDC 57237000114. Its NADAC has been published 396 times since Aug 9, 2017.
FDA first approved this application on Oct 7, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Rising Pharma Holdings Inc.NDC
57237000114
Classification
Generic
Dosage Form
KIT
Effective Date
11/19/2025
Approval Type
Generic (ANDA)
FDA Application
ANDA206006FDA Approved
10/7/2016
TE Code
AB
On Market Since
10/14/2016
Price Statistics
The NADAC for LANSOPRAZOL-AMOXICIL-CLARITHRO has been published 396 times since Aug 9, 2017, and over the history we have for it it has risen 89.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.0422 per EA |
|---|---|
| All-time high | $6.1168 (Nov 12, 2025) |
| All-time low | $2.3156 (Dec 19, 2018) |
| 52-week high | $6.1168 |
| 52-week low | $6.0422 |
| Median price | $4.7965 |
| Average price | $4.3010 |
| Largest weekly change | +62.1% (Oct 14, 2020) |
| Weeks tracked | 396 |
| Tracking since | Aug 9, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Lansoprazole, Amoxicillin, Clarithromycin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lansoprazole, Amoxicillin, Clarithromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LANSOPRAZOL-AMOXICIL-CLARITHRO?
The current National Average Drug Acquisition Cost (NADAC) for LANSOPRAZOL-AMOXICIL-CLARITHRO, manufactured by Rising Pharma Holdings Inc., is $6.0422 per EA (NDC 57237000114), effective Sep 30, 2026.
How has the price of LANSOPRAZOL-AMOXICIL-CLARITHRO changed over time?
Over the history we have for it, the NADAC for LANSOPRAZOL-AMOXICIL-CLARITHRO has risen 89.5%. It has been tracked across 396 weekly CMS publications since Aug 9, 2017.
What are the highest and lowest recorded NADAC prices for LANSOPRAZOL-AMOXICIL-CLARITHRO?
Since Aug 9, 2017, the NADAC for LANSOPRAZOL-AMOXICIL-CLARITHRO has ranged from a low of $2.3156 (Dec 19, 2018) to a high of $6.1168 (Nov 12, 2025), with a median of $4.7965 per EA.
Are there cheaper alternatives to LANSOPRAZOL-AMOXICIL-CLARITHRO?
No other NADAC-published product currently shares the active ingredient and strength of LANSOPRAZOL-AMOXICIL-CLARITHRO in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LANSOPRAZOL-AMOXICIL-CLARITHRO?
LANSOPRAZOL-AMOXICIL-CLARITHRO (NDC 57237000114) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.